American Century Companies Inc. Sells 106,813 Shares of Insulet Corporation $PODD

American Century Companies Inc. lowered its holdings in Insulet Corporation (NASDAQ:PODD) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,406,863 shares of the medical instruments supplier’s stock after selling 106,813 shares during the quarter. American Century Companies Inc. owned about 2.00% of Insulet worth $434,341,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. True Wealth Design LLC raised its holdings in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 72 shares during the last quarter. Golden State Wealth Management LLC grew its position in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares during the last quarter. Quent Capital LLC bought a new position in shares of Insulet during the 3rd quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. bought a new stake in shares of Insulet during the 2nd quarter worth $51,000.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $246.61 on Friday. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average price of $268.21 and a 200-day moving average price of $303.18. The company has a market cap of $17.36 billion, a price-to-earnings ratio of 70.46, a price-to-earnings-growth ratio of 1.50 and a beta of 1.41. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter in the previous year, the business posted $1.15 earnings per share. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insiders Place Their Bets

In related news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.39% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Evercore set a $340.00 price objective on Insulet in a report on Thursday, February 19th. The Goldman Sachs Group lowered their price target on shares of Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. BTIG Research restated a “buy” rating and set a $380.00 price target on shares of Insulet in a research note on Wednesday, February 18th. JPMorgan Chase & Co. reduced their price objective on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Finally, Raymond James Financial dropped their target price on Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $354.57.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.